Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | BRAF | P15056 | 3/20 | 0.40 |
| ▸ | KDR | P35968 | 3/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.38 |
| ▸ | GPR6 | P46095 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.37 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1230463 | 0.88 | EPHX2 (0.54) | SCDCSF1REPHX2 | |
| SCHEMBL1231156 | 0.87 | SCD (0.44) | SCDCSF1RBRAFKDR | |
| SCHEMBL1229145 | 0.84 | HRH1 (0.41) | SCDEPHX2GPR6NTRK1KCNH2 | |
| SCHEMBL1231030 | 0.84 | SCD (0.54) | SCDCSF1REPHX2LOXL2GPR6 | |
| SCHEMBL1230256 | 0.82 | SCD (0.45) | SCDEPHX2GPR6 | |
| SCHEMBL1230439 | 0.81 | SCD (0.67) | SCDCSF1R | |
| SCHEMBL1231202 | 0.80 | GPR6 (0.45) | SCDGPR6 | |
| SCHEMBL1230343 | 0.79 | SCD (0.41) | SCDCSF1REPHX2GPR6 | |
| SCHEMBL1230324 | 0.79 | CCR3 (0.48) | KCNH2 | |
| SCHEMBL1231168 | 0.78 | SCD (0.53) | SCDEPHX2GPR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946225-B2 | Derivatives of 2H pyridazin-3-ones, their preparation and their use as SCD-1 inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2015-02-03 | — | — | US | disclosed |
| US-8946225-B2 | Derivatives of 2H pyridazin-3-ones, their preparation and their use as SCD-1 inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2015-02-03 | — | — | US | disclosed |
| US-20120178678-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2012-07-12 | — | — | US | disclosed |
| US-20120178678-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2012-07-12 | — | — | US | disclosed |
| WO-2011015629-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2011-02-10 | — | — | WO | disclosed |
| WO-2011015629-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178678-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | SCD, SCD5, CYP2S1 | SCD 1/4885CSF1R 584/4885EPHX2 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.